Personal information

Other IDs

ResearcherID: P-8872-2014
Scopus Author ID: 35468172900

Activities

Collapse all

Works (50 of 299)

Items per page:
Page 1 of 6

Development of hyperdiploidy starts at an early age and takes a decade to complete

Blood
2025-01-30 | Journal article
DOI: 10.1182/blood.2024025250
Contributors: Mehmet K. Samur; Anil Aktas Samur; Parth Shah; Joseph S. Park; Mariateresa Fulciniti; Masood Shammas; Jill Corre; Kenneth C. Anderson; Giovanni Parmigiani; Hervé Avet-Loiseau et al.
Source: check_circle
Crossref

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma

Blood Advances
2023-11-14 | Journal article
DOI: 10.1182/bloodadvances.2023010025
Contributors: Mehmet Kemal Samur; Anil Aktas Samur; Jill Corre; Romain Lannes; Parth Shah; Kenneth Anderson; Hervé Avet-Loiseau; Nikhil Munshi
Source: check_circle
Crossref

Potential future direction of measurable residual disease evaluation in multiple myeloma

Blood
2023-11-02 | Journal article
DOI: 10.1182/blood.2023020284
Contributors: Mohamad Mohty; Hervé Avet-Loiseau; Florent Malard; Jean-Luc Harousseau
Source: check_circle
Crossref

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Blood
2023-03-30 | Journal article
DOI: 10.1182/blood.2022016212
Contributors: Nicholas Stong; María Ortiz-Estévez; Fadi Towfic; Mehmet Samur; Amit Agarwal; Jill Corre; Erin Flynt; Nikhil Munshi; Hervé Avet-Loiseau; Anjan Thakurta
Source: check_circle
Crossref

MRD in multiple myeloma: does CR really matter?

Blood
2022-12-08 | Journal article
DOI: 10.1182/blood.2022016170
Contributors: Bruno Paiva; Jesus San-Miguel; Hervé Avet-Loiseau
Source: check_circle
Crossref

Requirements for operational cure in multiple myeloma

Blood
2021-10-21 | Journal article
DOI: 10.1182/blood.2021012854
Contributors: Mohamad Mohty; Hervé Avet-Loiseau; Jean-Luc Harousseau
Source: check_circle
Crossref

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways

2021-09-05 | Other
DOI: 10.1101/2021.09.03.458836
Contributors: María Ortiz-Estévez; Mehmet Samur; Fadi Towfic; Erin Flynt; Nicholas Stong; In Sock Jang; Kai Wang; Paresh Vyas; Nikhil Munshi; Herve Avet-Loiseau et al.
Source: check_circle
Crossref

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Journal of Clinical Oncology
2021-04-01 | Journal article
DOI: 10.1200/JCO.20.01814
Contributors: Hervé Avet-Loiseau; Jesus San-Miguel; Tineke Casneuf; Shinsuke Iida; Sagar Lonial; Saad Z. Usmani; Andrew Spencer; Philippe Moreau; Torben Plesner; Katja Weisel et al.
Source: check_circle
Crossref

Risk factors in multiple myeloma: is it time for a revision?

Blood
2021-01-07 | Journal article
DOI: 10.1182/blood.2019004309
Contributors: Jill Corre; Nikhil C. Munshi; Hervé Avet-Loiseau
Source: check_circle
Crossref

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Leukemia
2019 | Journal article
DOI: 10.1038/s41375-018-0196-8
Contributors: Walker, B. A.; Mavrommatis, K.; Wardell, C. P.; Ashby, T. C.; Bauer, M.; Davies, F.; Rosenthal, A.; Wang, H.; Qu, P.; Hoering, A. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Carfilzomib weekly 20/56 mg/m

Am J Hematol
2019 | Journal article
DOI: 10.1002/ajh.25327
Contributors: Richez, V.; Gruchet, C.; Guidez, S.; Fouquet, G.; Azais, I.; Durand, G.; Javaugue, V.; Brigaud, A.; Plasse, F.; Diolez, J. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0037-9
Contributors: Bolli, N.; Biancon, G.; Moarii, M.; Gimondi, S.; Li, Y.; de Philippis, C.; Maura, F.; Sathiaseelan, V.; Tai, Y. T.; Mudie, L. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Leukemia
2018 | Journal article
DOI: 10.1038/leu.2017.345
Contributors: Maura, F.; Petljak, M.; Lionetti, M.; Cifola, I.; Liang, W.; Pinatel, E.; Alexandrov, L. B.; Fullam, A.; Martincorena, I.; Dawson, K. J. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

Biol Blood Marrow Transplant
2018 | Journal article
DOI: 10.1016/j.bbmt.2017.12.774
Contributors: Holstein, S. A.; Avet-Loiseau, H.; Hahn, T.; Ho, C. M.; Lohr, J. G.; Munshi, N. C.; Paiva, B.; Pasquini, M. C.; Tario, J. D.; Usmani, S. Z. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Haematologica
2018 | Journal article
DOI: 10.3324/haematol.2018.194118
Contributors: Spencer, A.; Lentzsch, S.; Weisel, K.; Avet-Loiseau, H.; Mark, T. M.; Spicka, I.; Masszi, T.; Lauri, B.; Levin, M. D.; Bosi, A. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Haematologica
2018 | Journal article
DOI: 10.3324/haematol.2018.194282
Contributors: Dimopoulos, M. A.; San-Miguel, J.; Belch, A.; White, D.; Benboubker, L.; Cook, G.; Leiba, M.; Morton, J.; Ho, P. J.; Kim, K. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment

Cancer Cell
2018 | Journal article
DOI: 10.1016/j.ccell.2018.02.007
Contributors: Nakamura, K.; Kassem, S.; Cleynen, A.; Chrétien, M. L.; Guillerey, C.; Putz, E. M.; Bald, T.; Förster, I.; Vuckovic, S.; Hill, G. R. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC

Bone Marrow Transplant
2018 | Journal article
DOI: 10.1038/s41409-018-0122-8
Contributors: Augeul-Meunier, K.; Chretien, M. L.; Stoppa, A. M.; Karlin, L.; Benboubker, L.; Diaz, J. M. T.; Mohty, M.; Yakoub-Agha, I.; Bay, J. O.; Perrot, A. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood
2018 | Journal article
DOI: 10.1182/blood-2017-07-795047
Contributors: Facon, T.; Dimopoulos, M. A.; Dispenzieri, A.; Catalano, J. V.; Belch, A.; Cavo, M.; Pinto, A.; Weisel, K.; Ludwig, H.; Bahlis, N. J. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0098-9
Contributors: Avet-Loiseau, H.; Facon, T.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Genomic patterns of progression in smoldering multiple myeloma

Nat Commun
2018 | Journal article
DOI: 10.1038/s41467-018-05058-y
Contributors: Bolli, N.; Maura, F.; Minvielle, S.; Gloznik, D.; Szalat, R.; Fullam, A.; Martincorena, I.; Dawson, K. J.; Samur, M. K.; Zamora, J. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients

Leukemia
2018 | Journal article
DOI: 10.1038/leu.2017.209
Contributors: Michallet, M.; Chapuis-Cellier, C.; Dejoie, T.; Lombard, C.; Caillon, H.; Sobh, M.; Moreau, P.; Attal, M.; Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

Leuk Lymphoma
2018 | Journal article
DOI: 10.1080/10428194.2017.1339876
Contributors: Fouquet, G.; Snell, K. I.; Guidez, S.; Schraen, S.; Boyle, E.; Renaud, L.; Desmier, D.; Machet, A.; Moya, N.; Systchenko, T. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood
2018 | Journal article
DOI: 10.1182/blood-2018-03-840132
Contributors: Walker, B. A.; Mavrommatis, K.; Wardell, C. P.; Ashby, T. C.; Bauer, M.; Davies, F. E.; Rosenthal, A.; Wang, H.; Qu, P.; Hoering, A. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Introduction to the review series on advances in multiple myeloma

Blood
2018 | Journal article
DOI: 10.1182/blood-2018-11-877795
Contributors: Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0116-y
Contributors: Samur, M. K.; Minvielle, S.; Gulla, A.; Fulciniti, M.; Cleynen, A.; Aktas Samur, A.; Szalat, R.; Shammas, M.; Magrangeas, F.; Tai, Y. T. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood
2018 | Journal article
DOI: 10.1182/blood-2018-06-858613
Contributors: Perrot, A.; Lauwers-Cances, V.; Corre, J.; Robillard, N.; Hulin, C.; Chretien, M. L.; Dejoie, T.; Maheo, S.; Stoppa, A. M.; Pegourie, B. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Multiple myeloma clonal evolution in homogeneously treated patients

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0153-6
Contributors: Corre, J.; Cleynen, A.; Robiou du Pont, S.; Buisson, L.; Bolli, N.; Attal, M.; Munshi, N.; Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow

Blood Adv
2018 | Journal article
DOI: 10.1182/bloodadvances.2018025197
Contributors: Mazzotti, C.; Buisson, L.; Maheo, S.; Perrot, A.; Chretien, M. L.; Leleu, X.; Hulin, C.; Manier, S.; Hébraud, B.; Roussel, M. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Cell Rep
2018 | Journal article
DOI: 10.1016/j.celrep.2018.12.016
Contributors: Fulciniti, M.; Lin, C. Y.; Samur, M. K.; Lopez, M. A.; Singh, I.; Lawlor, M. A.; Szalat, R. E.; Ott, C. J.; Avet-Loiseau, H.; Anderson, K. C. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Nucleotide excision repair is a potential therapeutic target in multiple myeloma

Leukemia
2018 | Journal article
DOI: 10.1038/leu.2017.182
Contributors: Szalat, R.; Samur, M. K.; Fulciniti, M.; Lopez, M.; Nanjappa, P.; Cleynen, A.; Wen, K.; Kumar, S.; Perini, T.; Calkins, A. S. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0040-1
Contributors: Ludwig, H.; Delforge, M.; Facon, T.; Einsele, H.; Gay, F.; Moreau, P.; Avet-Loiseau, H.; Boccadoro, M.; Hajek, R.; Mohty, M. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Prognosis of myeloma/genetics of myeloma

Neoplastic Diseases of the Blood
2018 | Book
Part of DOI: 10.1007/978-3-319-64263-5_35
EID:

2-s2.0-85047025733
Contributors: Robiou-Du-Pont, S.; Corre, J.; Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via Scopus - Elsevier

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside

Am Soc Clin Oncol Educ Book
2018 | Journal article
DOI: 10.1200/EDBK_200879
Contributors: Perrot, A.; Corre, J.; Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

Ann Hematol
2018 | Journal article
DOI: 10.1007/s00277-018-3236-6
Contributors: Fouquet, G.; Karlin, L.; Macro, M.; Caillot, D.; Roussel, M.; Arnulf, B.; Pegourie, B.; Petillon, M. O.; Mathiot, C.; Hulin, C. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

TIGIT immune checkpoint blockade restores CD8

Blood
2018 | Journal article
DOI: 10.1182/blood-2018-01-825265
Contributors: Guillerey, C.; Harjunpää, H.; Carrié, N.; Kassem, S.; Teo, T.; Miles, K.; Krumeich, S.; Weulersse, M.; Cuisinier, M.; Stannard, K. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Blood
2018 | Journal article
DOI: 10.1182/blood-2018-09-876433
Contributors: Cleynen, A.; Samur, M.; Perrot, A.; Buisson, L.; Maheo, S.; Fulciniti, M.; Attal, M.; Munshi, N.; Avet-Loiseau, H.; Corre, J.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.

Leukemia
2018-12 | Journal article
DOI: 10.1038/s41375-018-0339-y
PMID: 30573778
Contributors: Dejoie T; Corre J; Caillon H; Moreau P; Attal M; Loiseau HA
Source: Self-asserted source
Herve Avet-Loiseau via Europe PubMed Central

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Apollo - University of Cambridge Repository
2018-11-30 | Journal article
DOI: 10.17863/cam.33452
Contributors: Niccolo Bolli; Herve Avet-Loiseau; David Wedge; Peter Van Loo; Ludmil B. Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Professor Serena Nik-Zainal FMedSci; Graham R Bignell et al.
Source: check_circle
DataCite

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.

Apollo - University of Cambridge Repository
2018-11-23 | Journal article
DOI: 10.17863/cam.33125
Contributors: Niccolo Bolli; Y Li; V Sathiaseelan; K Raine; D Jones; Peter Ganly; F Cocito; G Bignell; Michael Chapman; AS Sperling et al.
Source: check_circle
DataCite

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Blood
2018-10 | Journal article
DOI: 10.1182/blood-2018-07-863829
PMID: 30282798
Contributors: Garderet L; Kuhnowski F; Berge B; Roussel M; Escoffre-Barbe M; Lafon I; Facon T; Leleu X; Karlin L; Perrot A et al.
Source: Self-asserted source
Herve Avet-Loiseau via Europe PubMed Central

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

2018-08 | Other
DOI: 10.1101/388611
OTHER-ID:

PPR47773
Contributors: Maura F; Bolli N; Angelopoulos N; Dawson KJ; Leongamornlert D; Martincorena I; Mitchell TJ; Fullam A; Gonzalez S; Szalat R et al.
Source: Self-asserted source
Herve Avet-Loiseau via Europe PubMed Central

[Circulating exosomal microRNA as biomarkers in mutiple myeloma]

Med Sci (Paris)
2017 | Journal article
DOI: 10.1051/medsci/20173311008
Contributors: Manier, S.; Leleu, X.; Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma

Front Physiol
2017 | Journal article
DOI: 10.3389/fphys.2017.00149
Contributors: Kendrick, F.; Evans, N. D.; Arnulf, B.; Avet-Loiseau, H.; Decaux, O.; Dejoie, T.; Fouquet, G.; Guidez, S.; Harel, S.; Hebraud, B. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

Leukemia
2017 | Journal article
DOI: 10.1038/leu.2017.344
Contributors: Bolli, N.; Biancon, G.; Moarii, M.; Gimondi, S.; Li, Y.; de Philippis, C.; Maura, F.; Sathiaseelan, V.; Tai, Y. T.; Mudie, L. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis

JAMA Oncol
2017 | Journal article
DOI: 10.1001/jamaoncol.2016.3160
Contributors: Munshi, N. C.; Avet-Loiseau, H.; Rawstron, A. C.; Owen, R. G.; Child, J. A.; Thakurta, A.; Sherrington, P.; Samur, M. K.; Georgieva, A.; Anderson, K. C. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Expressed fusion gene landscape and its impact in multiple myeloma

Nat Commun
2017 | Journal article
DOI: 10.1038/s41467-017-00638-w
Contributors: Cleynen, A.; Szalat, R.; Kemal Samur, M.; Robiou du Pont, S.; Buisson, L.; Boyle, E.; Chretien, M. L.; Anderson, K.; Minvielle, S.; Moreau, P. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Genomics of Multiple Myeloma

J Clin Oncol
2017 | Journal article
DOI: 10.1200/JCO.2016.70.6705
Contributors: Robiou du Pont, S.; Cleynen, A.; Fontan, C.; Attal, M.; Munshi, N.; Corre, J.; Avet-Loiseau, H.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Identification of miRSNPs associated with the risk of multiple myeloma

Int J Cancer
2017 | Journal article
DOI: 10.1002/ijc.30465
Contributors: Macauda, A.; Calvetti, D.; Maccari, G.; Hemminki, K.; Försti, A.; Goldschmidt, H.; Weinhold, N.; Houlston, R.; Andersen, V.; Vogel, U. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Blood
2017 | Journal article
DOI: 10.1182/blood-2017-06-791228
Contributors: Avet-Loiseau, H.; Bahlis, N. J.; Chng, W. J.; Masszi, T.; Viterbo, L.; Pour, L.; Ganly, P.; Palumbo, A.; Cavo, M.; Langer, C. et al.
Source: Self-asserted source
Herve Avet-Loiseau via ResearcherID
grade
Preferred source (of 2)‎
Items per page:
Page 1 of 6
How many people are using ORCID?